Cystatin c and blood pressure: Results of 24 h ambulatory blood pressure monitoring

European Journal of Internal Medicine

Volumn 21, Issue 3, 2010, Pages 185-190

  Mena, C ^a   Robles, N R ^b   de Prado, J Martín ^a   Gallego, F Garcia ^a   Cidoncha, A ^c  

^a Hospital de Don Benito   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c Laboratorio de Bioquímica Hospital de Don Benito Villanueva de la Serena   (Spain)

Author keywords

Blood pressure; Cystatin C; Hypertension; Kidney

Indexed keywords

ANTIHYPERTENSIVE AGENT; CREATININE; CYSTATIN C;

ADULT; AGE DISTRIBUTION; AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INVASIVE MEASUREMENT; PULSE PRESSURE;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION, RENAL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 77952290296     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.01.016     Document Type: Article

References (44)

1. Rule A.D., Larson T.S., Bergstralh E.J., Slezak J.M., Jacobsen S.J., and Cosio F.G. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 141 (2004) 929-937
2. Fliser D., and Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 37 (2001) 79-83
3. Newman D.J., Thakkar H., Edwards R.G., Wilkie M., White T., Grubb A.O., et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 47 (1995) 312-318
4. Laterza O.F., Price C.P., and Scott M.G. Cystatin C: an improved estimator of glomerular filtration rate?. Clin Chem 48 (2002) 699-707
5. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S.L., Newman A.B., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 (2005) 2049-2060
6. Shlipak M.G., Sarnak M.J., Katz R., Fried L., Seliger S., Newman A., et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 45 (2005) 268-271
7. Sarnak M.J., Greene T., Wang X., Beck G., Kusek J.W., Collins A.J., et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142 (2005) 342-351
8. Peralta C.A., Hicks L.S., Chertow G.M., Ayanian J.Z., Vittinghoff E., Feng L., and Shlipak M.G. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 45 (2005) 1-6
9. Peralta C.A., Whooley M.A., Ix J.H., and Shlipak M.G. Kidney function and systolic blood pressure new insights from cystatin C: data from the Heart and Soul Study. Am J Hypertens 19 (2006) 939-946
10. O'Brien E, Owens P. "Classic sphygmomanometry: a fin de siecle reappraisal." In Epidemiology of Hypertension. Ed, C. Bulpitt. Handbook of Hypertension. Series Eds. W.H.Birkenhager and J.L.Reid. Elsevier. Amsterdam. 2000 pp.130-151.
11. Mallion J.-M., Baguet J.-P., Siché J.-P., Tremel F., and De Gaudemaris R. Clinical value of ambulatory blood pressure monitoring. J Hypertens 17 (1999) 585-595
12. Pickering T.G., James G.D., Boddie C., Harshfield G.A., Blank S., and Laragh J.H. How common is white coat hypertension?. JAMA 259 (1988) 225-228
13. Staessen J.A., Byttebier G., Buntinx F., Celis H., O'Brien E., and Fagard R. For the ambulatory blood pressure monitoring and treatment investigators. Antihypertensive treatment based on conventional blood or ambulatory blood pressure measurement. A randomised controlled trial. JAMA 278 (1997) 1065-1072
14. Devereux R., Pickering T.G., Harshfield G.A., Kleinert H.D., Denby I., Clark L., et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 68 (1983) 470-476
15. Perloff D., Sokolow M., and Cowan R. The prognostic value of ambulatory blood pressure. JAMA 249 (1983) 2792-2798
16. Rowlands D.B., Ireland M.A., Glover D.R., McLeay R.A.B., Stallard T.J., and Littler W.A. The relationship between ambulatory blood pressure end echocardiographically assessed left ventricular hypertrophy. Clin Sci 61 Suppl.7 (1981) 101S-103S
17. Rizzoni D., Muiesan M.L., Montani G., Zulli R., Calebich S., and Agabiti-Rosei E. Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring. Am J Hypertens 5 (1992) 180-186
18. Manjunath G., Sarnak M.J., and Levey A.S. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens. 10 (2001) 785-792
19. Levey A., Bosch J., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
20. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39 suppl.1 (2002) S1-S246
21. Hoek F.J., Kemperman F.A., and Krediet R.T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 18 (2003) 2024-2031
22. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
23. O'Brien E., Asmar R., Beilin L., Imai Y., Mallion J.M., Mancia G., et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. European Society of Hypertension Working Group on Blood Pressure Monitoring (Review). J Hypertens 21 (2003) 821-848
24. Parikh N.I., Hwang S.J., Yang Q., Larson M.G., Guo C.Y., Robins S.J., et al. Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). Am J Cardiol 102 (2008) 1194-1198
25. Benetos B.W., Izzo J., Mitchell G., Resnick L., Asmar R., and Safar M. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 15 (2002) 1101-1108
26. Madero M., Wassel C.L., Peralta C.A., Najjar S.S., Sutton-Tyrrell K., Fried L., et al. Health ABC Study. Cystatin C associates with arterial stiffness in older adults. J Am Soc Nephrol 20 (2009) 1086-1093
27. Ix J.H., Katz R., De Boer I.H., Kestenbaum B.R., Allison M.A., Siscovick D.S., et al. Association of chronic kidney disease with the spectrum of ankle brachial index the CHS (Cardiovascular Health Study). J Am Coll Cardiol 54 (2009) 1176-1184
28. Nakamura K., Iizuka T., Takahashi M., Shimizu K., Mikamo H., Nakagami T., et al. Association between cardio-ankle vascular index and serum cystatin C levels in patients with cardiovascular risk factor. J Atheroscler Thromb 16 (2009) 371-379
29. Kuwajima I., Suzuki Y., Shimosawa T., Kanemaru A., Hoshino S., and Kuramoto K. Disminished nocturnal decline in blood pressure in elderly hypertensive patients with left ventricular hypertrophy. Am Heart J 67 (1992) 1307-1311
30. Redon J., Liao Y., Lozano J.V., Miralles A., Pascual J.M., and Cooper R.S. Ambulatory blood pressure in essential hypertension: role of circadian variability. J Hypertens 12 (1994) 947-953
31. Sturrock N.D., George E., Pound N., Stevenson J., Peck G.M., and Sowter H. Non-dipping diurnal blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabet Med 17 (2000) 360-364
32. Petrica L., Petrica M., Vlad A., Dragos Jianu C., Gluhovschi G., Ianculescu C., et al. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr 121 (2009) 765-775
33. Rosolowsky E.T., Ficociello L.H., Maselli N.J., Niewczas M.A., Binns A.L., Roshan B., et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 3 (2008) 706-713
34. Lee B.W., Ihm S.H., Choi M.G., and Yoo H.J. The comparison of cystatin C and creatinine as an accurate serum marker in the prediction of type 2 diabetic nephropathy. Diabetes Res Clin Pract 78 (2007) 428-434
35. Surendar J., Anuradha S., Ashley B., Balasubramanyam M., Aravindhan V., Rema M., et al. Cystatin C and cystatin glomerular filtration rate as markers of early renal disease in Asian Indian subjects with glucose intolerance (CURES-32). Metab Syndr Relat Disord 7 (2009) 419-425
36. Palatini P., Benetti E., Zanier A., Santonastaso M., Mazzer A., Cozzio S., et al. Cystatin C as predictor of microalbuminuria in the early stage of hypertension. Nephron Clin Pract 113 4 (2009) c309-c314
37. Coresh J., Byrd-Holt D., Astor B.C., Briggs J.P., Eggers P.W., Lacher D.A., et al. Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol 16 (2005) 180-188
38. Jones C.A., Francis M.E., Eberhardt M.S., Chavers B., Coresh J., Engelgau M., et al. Microalbuminuria in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 39 (2002) 445-459
39. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001) 421-426
40. Arnlov J., Evans J.C., Meigs J.B., Wang T.J., Fox C.S., Levy D., et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation 112 (2005) 969-975
41. Shlipak M.G., Katz R., Sarnak M.J., Fried L.F., Newman A.B., Stehman-Breen C., et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145 (2006) 237-246
42. Bostom A.G., Bausserman L., Jacques P.F., Liaugaudas G., Selhub J., and Rosenberg I.H. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine. Arterioscler Thromb Vasc Biol 19 (1999) 2241-2244
43. Boushey C.J., Beresford S.A.A., Omenn G.S., and Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for occlusive atherosclerosis. JAMA 472 (1995) 1049-1057
44. Omenn G.S., Beresford S.A.A., and Motulsky A.G. Preventing coronary heart disease: B-vitamins and homocysteine. Circulation 97 (1998) 421-424